

RECEIVED
CENTRAL FAX CENTER
JUN 17 2008

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

6/17/2008

FACSIMILE TRANSMISSION SHEET

TO: US PATENT AND
TRADEMARK OFFICE

+1 (571) 273-8300

FROM: NICHOLAS A. FAIRMAN

RE: US PATENT AND TRADEMARK; 30481/30010

PAGES (INCLUDING THIS PAGE): 6

Jacquelin Garcia

Legal Secretary
Marshall, Gerstein & Borun LLP
233 South Wacker Drive
6300 Sears Tower
Chicago, IL 60606-6357
Phone: (312) 474-9526
Fax: (312) 474-0448
E-mail: jgarcia@marshallip.com

If you do not receive all pages of this fax in good condition, please contact Jacquelin Garcia at (312) 474-6300.

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

RECEIVED
CENTRAL FAX CENTER

JUN 17 2008

FAX TRANSMISSION

DATE: June 17, 2008

PTO IDENTIFIER: Application Number 10/574,631
Patent Number

Inventor: Ozes et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (571) 273-8300

FROM: MARSHALL, GERSTEIN & BORUN LLP

Nicholas A. Fairman

PHONE: (312) 474-9587

Attorney Dkt. #: 30481/30010

PAGES (Including Cover Sheet): 5

CONTENTS:	Revocation of Power of Attorney or Authorization of Agent (1 page)
	Certificate of Transmission (1 page)
	Statement Under 37 CFR 3.73(b) (1 page)
	Schedule A (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (312) 474-9587 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300, Sears Tower, Chicago, Illinois 60606-6357
Telephone: (312) 474-6300 Facsimile: (312) 474-0448

RECEIVED
CENTRAL FAX CENTER

JUN 17 2008

PTO/SB/67 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Application No. (if known): 60/739,315

Attorney Docket No.: 30481/30019

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on June 17, 2008
Date



Signature

Nicholas A. Fairman

Typed or printed name of person signing Certificate

Registration Number, if applicable

(312) 474-9587

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Revocation of Power of Attorney or Authorization of Agent (1 page)
Statement Under 37 CFR 3.73(b) (1 page)
Schedule A (1 page)

RECEIVED
CENTRAL FAX CENTER

JUN 17 2008

PTOLSB/6: (01-05)

Approved for use through 12/31/2008. OMB 0551-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

I hereby revoke all previous powers of attorney given in the applications indicated on the Attached Schedule A sheet.

I hereby appoint:

<input checked="" type="checkbox"/> Practitioners associated with the Customer Number:	04743
--	-------

04743

OR

Pre

☐ Practitioner(s) named below:

Name	Registration Number	Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the applications indicated in the attached Schedule A sheet:

☒ The address associated with the above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature

Date

Name _____

Telephone

Title and Company

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

[illegible]

*Total of _____ forms are submitted.

RECEIVED
CENTRAL FAX CENTER

JUN 17 2008

PTO 85-003 (01-008)

Approved for use through 05/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: INTERMUNE, INC.

INTERMUNE, INC., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
(The extent (by percentage) of its ownership interest is _____ %)
in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent applications identified on the attached Schedule A sheet, to the current assignee are shown below.

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☒ All documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Shelly C. Danek
Signature

Date

Shelly C. Danek (Reg. No. 57.712)
Printed or Typed Name

(312) 474-6300
Telephone Number

Authorized Signer for Assignee
Title

Schedule A
InterMune, Inc.

Client	Matter	Inventor	Application Number	Application Filing Date	Title	Reel/Frame
30481	30006	Phillips et al.	60/731,661	10/31/2005	Pirfenidone/Toll-Like Receptor (TLR) Agonist Compositions and Methods for Using Them to Stimulate Production of Granulocyte Colonizing Stimulating Factor (G-CSF)	017648/0267
30481	30007	Robinson et al.	60/741,976	12/02/2005	Methods of Reducing Adverse Events Associated with Pirfenidone Therapy	020029/0919
30481	30010	Ozes et al.	10/574,631	1/31/2007	Use of Pirfenidone in Therapeutic Regimens	018835/0672
30481	30011	Blatt	60/471,043	5/16/2003	Type I Interferon Receptor Agonists and IP-10 Combination Therapy for Cancer Treatment	014477/0628
30481	30012	Blatt	60/471,129	5/16/2003	IP-30 and Pirfenidone Combination Therapy for Cancer Treatment	015241/0182
30481	30013	Blatt	60/471,179	5/16/2003	Pirfenidone Combination Therapy for Cancer Treatment	014100/0961
30481	30014	Blatt	60/471,249	5/16/2003	Type I Interferon Receptor Agonist and Pirfenidone Combination Therapy for Cancer Treatment	014350/0754
30481	30015	Blatt et al.	60/476,711	6/06/2003	Methods of Treating TNF-Mediated Disorders	014100/0825
30481	30018	Olgin et al.	60/732,676	11/01/2005	Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds	017332/0311
30481	30019	Seiwert et al.	60/739,315 60/775,823 60/793,526	11/23/2005 2/21/2006 4/20/2006	Method of Modulating Stress-Activated Protein Kinase System	109852/0694 018168/0935 017951/0134